Offering new hope for back pain sufferers, Dr. Roger Härtl and the multidisciplinary spine team at the Weill Cornell Brain and Spine Center are now recruiting patients for a new clinical trial. The trial will test an investigational medication intended to treat low back pain and disability caused by spinal disc disease.

The injectable medication, named NuQu, is made of cartilage cells and is delivered during a short, one-time treatment. Trial participants will go home within an hour...

Dr. Athos Patsalides is now enrolling patients in a Phase I research study on spinal metastatic disease (SMD). This new trial will test the safety of a new minimally invasive treatment called spinal intra-arterial chemotherapy (SIAC) in patients with SMD.

As many as 10 percent of cancer patients will develop a metastatic spinal tumor during the course of their disease — metastasis from another cancer is the most common cause of malignant spinal tumors in adults. The most devastating...